Echo Street Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Echo Street Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,612	Closed	-$573K	–	469
2023 Q2	$573K	Buy	6,612 +4,336	+191%	+$408K	﹤0.01%	231
2023 Q1	$221K	Buy	+2,276	New	+$236K	﹤0.01%	446
2022 Q4	–	Sell	-9,729	Closed	-$825K	–	506
2022 Q3	$825K	Buy	+9,729	New	+$866K	0.01%	184
2022 Q2	–	Sell	-14,612	Closed	-$1.13M	–	573
2022 Q1	$1.13M	Buy	+14,612	New	+$1.22M	0.01%	201
2021 Q3	–	Sell	-5,009	Closed	-$418K	–	635
2021 Q2	$418K	Buy	5,009 +1,730	+53%	+$137K	﹤0.01%	415
2021 Q1	$248K	Buy	+3,279	New	+$268K	﹤0.01%	456

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Echo Street Capital Management's BMRN Position: Q3 2023 in Review

Echo Street Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 6,612 shares — an estimated $573K sold.

Echo Street Capital Management first reported a position in BMRN in Q1 2021 and held it in 6 quarters. The position peaked at $1.13M in Q1 2022. 520 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Echo Street Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Echo Street Capital Management sold 6,612 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $573K.
Echo Street Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 6 quarters.
Echo Street Capital Management's BioMarin Pharmaceuticals position peaked at $1.13M in Q1 2022.
520 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Echo Street Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.